US 7,582,287 B2Grant

Method for treating cervical cancer

Issue Date:2009-09-01

•15 Claims

Abstract

Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.

Metadata

Assignee

Zymogenetics, Inc.

Inventors

Yasmin A. Chandrasekher
Patricia A. McKernan

Application Information

Application Number:US 10/321,163

Filing Date:2002-12-17

Priority Date:2001-12-17

Art Unit:1643

Classifications

IPC:

A61K38/19

Patent Drawings

This patent does not have any drawings.

Description

[0001] This claims the benefit under 35 U.S.C. § 119 (e) of U.S. Provisional Application No. 60/341,783 filed on Dec. 17, 2001.

BACKGROUND OF THE INVENTION

[0002] According to the American Cancer Society, 12,800 new cases of invasive cervical cancer would be diagnosed in the United States in 1999. During the same year, 4800 patients were expected to die of the disease. This represents approximately 1.8% of all cancer deaths in women and 18% of gynecological cancer deaths. However, for women aged 20 to 39 years of age, cervical cancer is the second leading cause of cancer deaths. Molecular and epidemiologic studies have demonstrated a strong relationship between human papillomavirus (HPV), cervical intraepithelial neoplasia, (CIN), and invasive carcinoma of the cervix. Thus, there is a need to develop new therapeutic entities for the treatment of human papillomavirus infection, cervical intraepithelial neoplasia and carcinoma of the cervix.

DESCRIPTION OF THE INVENTION

[0003] The present invention fills this need by administering interleukin-20 (IL-20) to a mammalian having cervical cancer. IL-20 can also be used to treat a human papillomavirus infection. The present invention also provides a method for inhibiting the growth of cervical cancer cells by bringing IL-20 into contact with said cancerous cervical cells. Interleukin-20 (formally called Zcyto10) can be produced according to the method described in International Patent Application No. PCT/US98/25228 filed on Nov. 25, 1998. The human IL-20 polypeptide is comprised of a sequence of 176 amino acids with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. It is believed that amino residues 1-24 are signal sequence, and the mature IL-20 polypeptide is represented by the amino acid sequence comprised of residues 25, a leucine, through amino acid residue 176, a glutamic acid residue, also defined by SEQ ID NO:12. Another embodiment of the present invention is defined by the sequences of SEQ ID NO:3 and SEQ ID NO:4. The polypeptide of SEQ ID NO:4 is comprised of 151 amino acid residues wherein amino acids 1-24 comprise a signal sequence and the mature sequence is comprised of amino acid residues 25, a leucine, through amino acid 151 a glutamic acid, also defined by SEQ ID NO:13. Another active variant is comprised of amino acid residues 33, a cysteine, through amino acid residue 176 of SEQ ID NO:2. This variant is also defined by SEQ ID NO:26.

[0004] Mouse IL-20 is also a polypeptide comprised of 176 amino acid residues as defined by SEQ ID NOs:18 and 19. Mouse IL-20 has a signal sequence extending from amino acid residue 1, a methionine, extending to and including amino acid residue 24, a glycine of SEQ ID NO:19. Thus, the mature mouse IL-20 extends from amino acid residue 25, a leucine, to and including amino acid residue 176 a leucine of SEQ ID NO:19, also defined by SEQ ID NO:20. Another active variant is believed to extend from amino acid 33, a cysteine, through amino acid 176, of SEQ ID NO:19. This variant is also defined by SEQ ID NO:25.

[0005] A variant of mouse IL-20 is defined by SEQ ID NOs:33 and 34. This variant is 154 amino acid residues in length and has a signal sequence extending from amino acid residue 1, a methionine, to and including amino acid residue 24, a glycine, of SEQ ID NO:34. Thus, the mature sequence extends from amino acid residue 25, a leucine, to and including amino acid residue 154, a leucine, of SEQ ID NO:34. The mature sequence is also defined by SEQ ID NO:35.

Pathology of Cervical Cancer

[0006] Cervical dysplasia cells and cervical intraepithelial neoplasia (CIN) cells develop into invasive cervical cancer over a number of years. CIN grades I, II and III correspond to mild, moderate, and severe cervical dysplasia. CIN III, which includes severe dysplasia and carcinoma in situ, is unlikely to regress spontaneously and, if untreated, may eventually penetrate the basement membrane, becoming invasive carcinoma. Squamous cell carcinoma accounts for 80 to 85% of all cervical cancers; adenocarcinomas account for most of the rest. Invasive cervical cancer usually spreads by direct extension into surrounding tissues and the vagina or via the lymphatics to the pelvic and para-aortic lymph nodes drained by the cervix. Hematologic spread is possible.

Symptoms, Signs and Diagnosis of Cervical Cancer

[0007] CIN is usually asymptomatic and discovered because of an abnormal Pap smear. Patients with early-stage cervical cancer usually present with irregular vaginal bleeding, which is most often postcoital, but intermenstrual bleeding or menometrorrhagia may occur. Patients with larger cervical cancers or advanced-stage disease may present with foul-smelling vaginal discharge, abnormal vaginal bleeding, or pelvic pain. Obstructive uropathy, back pain, and leg swelling are manifestations of late-stage disease. Suspicious lesions, generally first detected by a Pap smear are biopsied. If clinical disease is invasive, staging is performed on the basis of the physical examination, with a metastatic survey including cystoscopy, sigmoidoscopy, IV pyelography, chest x-ray, and skeletal x-rays.

Treatment of Cervical Cancer with IL-20

[0008] Cervical cancer can be treated by administration of IL-20 to a female mammal, particularly a human female, afflicted with the disease. IL-20 can be administered intralesionally, or intramuscularly for localized disease. For metastatic disease, IL-20 can also be administered by intraperitoneal administration including intravenous administration. IL-20 can be administered alone or in conjunction with standard therapies such as surgery, radiation or other chemotherapeutic agents such as bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

Use of Interleukin-20 to Treat Cells Infected with the Human Papillomavirus/Genital Warts

[0009] Cells infected with the human papillomavirus (HPV) can be treated with IL-20 to inhibit the proliferation of the virus. Anogenital warts caused by HPV type 6, 11, 16, 18, 31, 33 and 35 are transmitted sexually and have an incubation period of 1 to 6 months. Endocervical wart infections caused by type 16 or 18 have been implicated as a cause of cervical intraepithelial neoplasia and cervical cancer. HPV types 16 and 18 generally do no not cause external genital warts, which are usually caused by types 6 and 11.

Symptoms, Signs and Diagnosis

[0010] Genital warts usually appear as soft, moist, minute pink or gray polyps that enlarge, may become pedunculated, and are usually found in clusters. The surfaces resemble the surface of cauliflower. In men they occur most commonly on warm, moist surfaces in the subpreputial area, on the coronal sulcus, within the urethral meatus, and on the penile shaft. In women, the vulva, the vaginal wall, the cervix, and the perineum may become involved. They are particularly common in the perianal region and rectum in homosexual men. Growth rates vary, but pregnancy, immunosuppression, or maceration of the skin may accelerate both the growth of individual lesions and their spread. Genital warts usually can be identified by their appearance but must be differentiated from the flat-topped condyloma lata of secondary syphilis. Biopsies of a typical or persistent warts may be necessary to exclude carcinoma.

[0011] IL-20 can be administered directly into lesions containing cells infected with HPV alone or with standard therapies such as interferon alpha or interferon beta both of which are commercially available. Interferon alpha is available from Schering Corporation of Kenilworth, N.J. and is called INTRON A®. Interferon beta is produced by Biogen of Cambridge, Mass. and is called AVONEX®. IL-20 can also be administered with other standard therapies for treating HPV including antimitotics such as podophyllotoxin, podophyllin, or 5-fluorouracil; caustics such as trichloroacetic acid; or interferon inducers such as imiquimod.

[0012] The quantities of IL-20 for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medications administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in vivo administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Methods for administration include, intravenous, peritoneal, intramuscular, or intralesional. Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 1 μg to 1000 μg per kilogram of body weight per day. However, the doses may be higher or lower as can be determined by a medical doctor with ordinary skill in the art. Excipients and stabilizers can possible be added. These include glycine, histidine, glutamate, aspartate, sugars, sucrose, trehalose, galactose sorbitol, arginine, D-and/or L0amino acids, sugar alcohols, lactose, maltose, threonine, lysine, methionine, isoleucine, a surface active agent such as TWEEN 80, TWEEN 20, polyethylene glycol (PEG) (particularly those PEGs having molecular weights between 1000 and 35000 Da), cetyl alcohol, polyvinylpyrrolidone, polyvinyl alcohol, lanolin alcohol and sorbitan. A reducing agent may be included, such as cysteine, N-acetyl-cysteine, and thioglycerol. For a complete discussion of drug formulations and dosage ranges see Remington's Pharmaceutical Sciences,18^thEd., (Mack Publishing Co., Easton, Pa., 1996), and Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 9^thEd. (Pergamon Press 1996).

[0013] IL-20 can also me administered in conjunction with other treatments for cervical cancer such as radiation and chemotherapy. Examples of chemotherapeutic agents include bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

EXAMPLE

[0014] We tested IL-20 in a HeLa299 cytotoxicity assay to measure the ability of IL-20 to prevent cells from growing during normal growth conditions. We used MTT reagent (Promega, Madison, USA) as our detection and readout for this cell inhibition assay. Procedure of a cytoxicity assay:

[0015] Day 1—Plate cells out in complete growth media (with serum) at 5000 cells/well in a 96 well format and let them incubate overnight at 37 degrees and 5% CO2.

[0016] Day 2—Dump off media and add a dose response of appropriate ligands in complete growth media (IL-20, zmda1, and MDA7 at 10, 100, and 1000 ng/ml.), along with a positive control retinoic acid (100 uM) in complete growth media, while leaving some wells in complete growth media as controls of how the cells normally grow under normal conditions. Put the cells in incubator and let the assay go for 72 hrs.

[0017] Day 5—Add 15 ul/well of MTT reagent, let cells inc. for 4 hrs., then add 100 ul of stop solution, let cells inc. for an additional 1 hr., then read the plate on a multilabel counter (Victor2, PerkinElmer Life Sciences Inc., Boston). The MTT protocol will give you two readings, one at a 650 wavelength (background) and one at a 572 wavelength. Subtract the 650 reading from the 572 reading to get your actual output. These numbers are averaged and converted to a % inhibition value.

RESULTS

- [0018] Retnoic acid gave a 53% inhibition of growth (positive control)
- [0019] IL-20 gave a maximal 20% inhibition of growth

Claims

Certificate of Correction present

The claims shown below may not include correction changes. Use the corrected PDF for authoritative text.

What is claimed is:

1. A method for inhibiting the growth and or proliferation of cervical cancer cells comprising bringing an Interleukin-20 (IL-20) polypeptide into contact with the cervical cancer cells.

2. The method of claim 1, wherein the cervical cancer cells are treated with radiation in conjunction with the IL-20 polypeptide.

3. The method of claim 1, wherein the cervical cancer cells are treated with one or more chemotherapeutic agents in conjunction with the IL-20 polypeptide.

4. The method of claim 3, wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

5. A method for inhibiting the growth and or proliferation of cervical cancer cells comprising bringing a polypeptide comprising amino acid residues 33-176 of SEQ ID NO:2 into contact with the cervical cancer cells.

6. The method of claim 5, wherein the cervical cancer cells are treated with radiation in conjunction with the polypeptide.

7. The method of claim 5, wherein the cervical cancer cells are treated with one or more chemotherapeutic agents in conjunction with the polypeptide.

8. The method of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

9. The method of claim 5, wherein the polypeptide comprises amino acid residues 25-176 of SEQ ID NO:2.

10. The method of claim 5, wherein the polypeptide comprises amino acid residues 1-176 of SEQ ID NO:2.

11. A method for inhibiting the growth and or proliferation of cervical cancer cells comprising bringing a polypeptide comprising amino acid residues 25-151 of SEQ ID NO:4 into contact with the cervical cancer cells.

12. The method of claim 10, wherein the cervical cancer cells are treated with radiation in conjunction with the polypeptide.

13. The method of claim 10, wherein the cervical cancer cells are treated with one or more chemotherapeutic agents in conjunction with the polypeptide.

14. The method of claim 12, wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

15. The method of claim 10, wherein the polypeptide comprises amino acid residues 1-151 of SEQ ID NO:4.

Patent Citations (35)

Patent	Date	Inventor	Cited By
US5723299(A)	1998-03-01	Bell et al.	Applicant
US5789192(A)	1998-08-01	Moore et al.	Applicant
US5843725(A)	1998-12-01	Sledziewski et al.	Applicant
US5945511(A)	1999-08-01	Lok et al.	Applicant
US5985614(A)	1999-11-01	Rosen et al.	Applicant
US6020163(A)	2000-02-01	Conklin	Applicant
US6486301(B1)	2002-11-01	Ebner et al.	Applicant
US6576743(B1)	2003-06-01	Conklin et al.	Applicant
US6610286(B2)	2003-08-01	Thompson et al.	Applicant
US2002/0042366(A1)	2002-04-01	Thompson et al.	Applicant
WO94/13801	1994-06-01		Applicant
WO99/03982	1999-01-01		Applicant
WO99/07740	1999-02-01		Applicant
WO99/07848	1999-02-01		Applicant
WO99/27103	1999-06-01		Applicant
WO99/37772	1999-07-01		Applicant
WO99/46281	1999-09-01		Applicant
WO99/46379	1999-09-01		Applicant
WO99/61630	1999-12-01		Applicant
WO/12708	2000-03-01		Applicant
WO/15264	2000-03-01		Applicant
WO/39161	2000-07-01		Applicant
WO/42189	2000-07-01		Applicant
WO/42189	2000-07-01		Examiner
WO/73457	2000-12-01		Applicant
WO/78961	2000-12-01		Applicant
WO1/12672	2001-02-01		Applicant
WO1/46261	2001-06-01		Applicant
WO2/12345	2002-02-01		Applicant
WO2/058724	2002-08-01		Applicant
WO2/070001	2002-09-01		Applicant
WO2/072607	2002-09-01		Applicant
WO3/039444	2003-05-01		Applicant
WO3/051384	2003-06-01		Applicant
WO2004/085475	2004-10-01		Applicant

Non-Patent Literature (115)

Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.Examiner
Dermer (Bio/Technology, 1994, 12:320).Examiner
Gura (Science, v278, 1997, pp. 1041-1042).Examiner
Shi et al (J. Biol Chem Jun. 2000;275(25):19167-19176).Examiner
Rose (Cancer J. Mar.-Apr. 2001;7(2):86-92).Examiner
Clerici et al J. Natl. Can. Inst. 1997; 89(3):245-250.Examiner
Abbas et al., “Cellular and Molecular Immunology”, 4th Ed., pp. 519-520, W.B. Saunders Company, 2000.Applicant
Albert et al., “Molecular Biology of the Cell,” 3rd Ed., pp. 156-159, Garland Publishing, Inc., 1994.Applicant
Asadullah et al., Arch Dermatol 138:1189-1196, 2002.Applicant
Asadullah et al., Pharmacol Rev. 55(2):241-269, 2003.Applicant
Blumberg et al., Cell 104:9-19, 2001.Applicant
Cameron et al., “Cytokines and Chemokines in Autoimmune Disease,” pp. 8-32, Eurekah.com and Klawer Academic/Plenum Publishers, 2003.Applicant
Conti et al., Immunology Letters 88:171-174, 2003.Applicant
Cunningham et al., Science 244:1081-1805, 1989.Applicant
Davis et al., Cell 87:1161-1169, 1996.Applicant
De Groot-Kruseman et al., J. Interferon & Cytokine Research 22(Suppl. l):S-97, Abstract P-2-1, 2002.Applicant
Dumoutier et al., Eur. Cytokin Netw 13(2):5-15, 2002.Applicant
Dumoutier et al., J. Immunol. 167:3545-3549, 2001.Applicant
Dynan et al., Nature 316:774-778; 1985.Applicant
Fickenscher et al., Trends in Immunology 23(2):89-96, 2002.Applicant
George et al., “Macromolecular Sequencing & Synthesis,” pp. 127-149, Ch. 12, Alan R. Liss, Inc., 1988.Applicant
Gröne, Veterinary Immunol. And Immunopathal. 88:1-12, 2002.Applicant
Harlow et al., “Antibodies A Laboratory Manual,” p. 76, Ch. 5, Cold Springs Harbor Laboratory, 1988.Applicant
He et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-97, Abstract P-1-23, 2002.Applicant
Henikoff et al., Proc. Nat. Acad. Sci. USA 89:10915-10919, 1992.Applicant
Hosoi et al., The 75th Annual Meeting, Department of Pharmacology, Kumamoto University, p. 89P, Abstract P-112, 2002.Applicant
Kotenko, Cytokine & Growth Factor Reviews 13:223-240, 2002.Applicant
Kotenko et al., J. Biol. Chem. 276(4):2725-2732, 2001.Applicant
Kotenko et al., Oncogone 19:2557-2565, 2000.Applicant
Kunz et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-97-S-98, Abstract P-2-3, 2002.Applicant
Last et al., J. Investigative Dermatology 119(1):325, Abstract 707, 2002.Applicant
Liu et al., Blood 100(11):189a-190a, Abstract #710, 2002.Applicant
Liu et al., Journal of Immunology 152:1821-1829, 1994.Applicant
Liu et al., Blood 102(9):3206-3209; 2003.Applicant
Lutfalla et al., Genomics 16:366-373, 1993.Applicant
Lutfalla et al., J. Mol. Evolution 41:338-344, 1995Applicant
Lillehoj et al., “Antibody Techniques,” pp. 291-305, Ch. 13, Academic Press, Inc., 1994.Applicant
McKinnon et al., Drug News and Perspectives 9(7):389-398, 1996.Applicant
Merck Manual 17th Ed., pp. 920-925.Applicant
Mohler et al., FASB J. US Fed of American Soc. For Experimental Biology 6(4):A1123, 1992.Applicant
Musso et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-98, Abstract P-2-4, 2002.Applicant
Ozaki et al., J. Biol. Chem.0 277(33):29355-29358, 2002.Applicant
Parrish-Novak et al., J. Biol. Chem 277(49):47517-47523, 2002.Applicant
Parrish-Novak et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-46, Abstract W-1-5, 2002.Applicant
Pirhonen et al., J. Interferon & Cytokine Research 22(Suppl. 1): S-98, Abstract P-2-6, 2002.Applicant
Ramesh et. al., Cancer Gene Therapy: S3, Abstract 008, 2002.Applicant
Rich et al., Curr Biol. 11(13):R531-R534, 2001.Applicant
Rich, Expert Opin. Ther. Targets 7(2):165-174, 2003.Applicant
Rohovsky et al., “Growth Factors and Wound Healing” pp. 8-26, Ch. 2; Springer, 1997.Applicant
Roitt et al., “Immunology,” 4th Ed., pp. 28.10-28.12, Mosby, 1996.Applicant
Rose-John, Acta Biochimica Polonica 50(3):603-611, 2003.Applicant
Salazar et al., Eur. J. of Clin. Invest. 31(12):1070-1077, 2001.Applicant
Slavin, J. Immunol. Immunopharmacol 17(1):25-29, 1997.Applicant
Stolina et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-98-S-99, Abstract P-2-7, 2002.Applicant
Strengell et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-99, Abstract P-2-8, 2002.Applicant
Tachiiri et al., Genes and Immunity 4: 153-159, 2003.Applicant
Vandenbroeck et al., J. Biol. Chem. 277(28):25668-25676, 2002.Applicant
Volk et al., Trends in Immunology 22(8):414-417, 2001.Applicant
Walter, Immunologic Res. 26(1-3):303-308, 2002.Applicant
Whitters et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-99-S-100, Abstract P-2-11, 2002.Applicant
Witek et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-100, Abstract P-2-12, 2002.Applicant
Wolk et al., J. Immunol. 168:5397-5402, 2002.Applicant
Wuyts et al., Eur J. Biochem. 260:421-429, 1999.Applicant
Xie et al., J. Biol. Chem. 275(40):31335-31339, 2000.Applicant
Xu et al., Proc. Nat. Acad. Sci. USA. 98(17):9511-9516, 2001.Applicant
EST from Incyte Pharmaceuticals Inc., INC1429789, 1996.Applicant
EST from Incyte Pharmaceuticals Inc., INC1922140, 1996.Applicant
EST from Incyte Pharmaceuticals Inc., INC1923851, 1996.Applicant
EST from Incyte Pharmaceuticals Inc., INC2119350, 1996.Applicant
EST from Incyte Pharmaceuticals Inc., INC2270605, 1996.Applicant
EST from Incyte Pharmaceuticals Inc., INC2699058, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC2701079, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC2720417, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC2763478, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC3256488, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC3257185, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC3316826, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC3376533, 1997.Applicant
EST from Incyte Pharmaceuticals Inc., INC357666, 1995.Applicant
EST from Incyte Pharmaceuticals Inc., INC4304592, 1998.Applicant
EST from Incyte Pharmaceuticals Inc., INC758088, 1996.Applicant
EST from Incyte Pharmaceuticals Inc., INC819592, 1996.Applicant
EST from Incyte Pharmaceuticals Inc., INC904360, 1996.Applicant
EST from TIGR Tentative Human Consensus, THC174656, 1997.Applicant
EST from TIGR Tentative Human Consensus, THC197949, 1997.Applicant
EST from TIGR Tentative Human Consensus, THC215509, 1997.Applicant
GenBank Accession No. AA018585, 1995.Applicant
GenBank Accession No. AA018749, 1995.Applicant
GenBank Accession No. AA035594, 1995.Applicant
GenBank Accession No. AA132964, 1995.Applicant
GenBank Accession No. AA134881, 1995.Applicant
GenBank Accession No. AA135185, 1995.Applicant
GenBank Accession No. AA135300, 1995.Applicant
GenBank Accession No. AA299011, 1995.Applicant
GenBank Accession No. AA412292, 1997.Applicant
GenBank Accession No. AA470014, 1997.Applicant
GenBank Accession No. AA494556, 1997.Applicant
GenBank Accession No. AA514541, 1997.Applicant
GenBank Accession No. AA516435, 1997.Applicant
GenBank Accession No. AA528216, 1997.Applicant
GenBank Accession No. AA583432, 1997.Applicant
GenBank Accession No. AA632915, 1997.Applicant
GenBank Accession No. H17201, 1995.Applicant
GenBank Accession No. H17978, 1995.Applicant
GenBank Accession No. N62509, 1995.Applicant
GenBank Accession No. N79409, 1995.Applicant
GenBank Accession No. R14678, 1995.Applicant
GenBank Accession No. R42401, 1995.Applicant
GenBank Accession No. T70354, 1995.Applicant
GenBank Accession No. T70439, 1995.Applicant
International Search Report from PCT/US02/40309.Applicant
Supplementary Partial European Search Report from counterpart European Application No. EP 02 80 518.1.Applicant
Supplementary European Search Report from counterpart European Application No. EP 02 80 518.1.Applicant
Article 94(3) EPC Communication dated Dec. 13, 2007.Applicant
Article 94(3) EPC Communication dated Dec. 9, 2008.Applicant